Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.04 | 0.7 |
mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.018 | 0.7 |